SCHEMBL3318017

SCHEMBL3318017

NC(=O)c1ncc[nH]1.O=C(O)c1ccc(-c2csc3ccccc23)c2nccnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 1/20 0.43
CDC7 O00311 1/20 0.39
CSNK1A1 P48729 1/20 0.38
TYRO3 Q06418 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
APP P05067 2/20 0.34
CYP2C9 P11712 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
F2RL1 P55085 1/20 0.33
JUN P05412 1/20 0.32
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
KDM4E B2RXH2 2/20 0.32
KDM6B O15054 1/20 0.32
KDM6A O15550 1/20 0.32
TET3 O43151 1/20 0.32
KDM4A O75164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318023 0.88 FGFR3 (0.44) FGFR3CDC7CSNK1A1TYRO3DYRK1B
SCHEMBL1126390 0.86 FGFR3 (0.49) FGFR3CDC7APPCYP2C9ALDH1A1
SCHEMBL1126631 0.78 FGFR3 (0.59) FGFR3CDC7APPCYP2C9ALDH1A1
SCHEMBL3316159 0.77 MYC (0.41) FGFR3CSNK1A1TYRO3DYRK1BALDH1A1
SCHEMBL17023018 0.70 FGFR3 (0.45) FGFR3CDC7APPCYP2C9ALDH1A1
SCHEMBL4332010 0.70 FGFR3 (0.53) FGFR3ALDH1A1KMT2AKDM4EL3MBTL1
Biphenyl SCHEMBL27718930 0.67 CSNK1A1 (0.49) CSNK1A1TYRO3DYRK1BALDH1A1KMT2A
SCHEMBL3316051 0.67 FGFR3 (0.51) FGFR3
SCHEMBL15025427 0.66 APP (0.50) APPCYP2C9ALDH1A1RAB9AHSD17B10
SCHEMBL1126238 0.66 KDM4E (0.52) ALDH1A1KMT2ARAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105667-A1 Quinoxaline- and Quinoline-Carboxamide Derivatives NOVARTIS AG 2010-04-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105667-A1 Quinoxaline- and Quinoline-Carboxamide Derivatives ABL1, NQO2, MAP4K5 FGFR3 1515/4885CDC7 927/4885CSNK1A1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.